Primary Ovarian Insufficiency (POI) affects~1% of women under forty. Exome sequencing of two Finnish sisters with non-syndromic POI revealed a homozygous mutation in FANCM, leading to a truncated protein (p.Gln1701*). FANCM is a DNA-damage response gene whose heterozygous mutations predispose to breast cancer. Compared to the mother's cells, the patients' lymphocytes displayed higher levels of basal and mitomycin C (MMC)-induced chromosomal abnormalities. Their lymphoblasts were hypersensitive to MMC and MMC-induced monoubiquitination of FANCD2 was impaired. Genetic complementation of patient's cells with wild-type FANCM improved their resistance to MMC re-establishing FANCD2 monoubiquitination. FANCM was more strongly expressed in human fetal germ cells than in somatic cells. FANCM protein was preferentially expressed along the chromosomes in pachytene cells, which undergo meiotic recombination. This mutation may provoke meiotic defects leading to a depleted follicular stock, as in Fancm -/mice. Our findings document the first Mendelian phenotype due to a biallelic FANCM mutation.
Introduction
Primary Ovarian Insufficiency (POI) affects about 1% of women under forty years. It is often diagnosed too late, thus generating infertility and significant morbidity and mortality due to steroid-deprivation associated symptoms. Infertility is usually definitive but resumption of ovarian function occurs in~24% of cases (Tucker et al., 2016) . POI is etiologically heterogeneous (OMIM: ODG1 # 233300. ODG2 # 300510 ODG3 # 614324, ODG4 # 616185) and remains idiopathic in~70% of the
Results
The two POI patients belong to a consanguineous family ( Figure 1A) without history of cancer. The parents and the 20 year old brother are reported as healthy, and the mother had regular menses at eLife digest About one in 100 women under the age of 40 experience a condition known as primary ovarian insufficiency, which is sometimes known as premature menopause. Women with this condition may have fewer egg cells and are usually infertile. Women with primary ovarian insufficiency are also more at risk of other diseases, including the bone disorder osteoporosis and cardiovascular diseases. The condition is thought to have a genetic basis in part, although so far its causes are largely unknown.
Fouquet, Pawlikowska et al. looked at all the genes in genomes of three women in one Finnish family: two sisters and their mother. Both of the sisters had primary ovarian insufficiency, but were otherwise healthy. Their mother did not have the condition. The genetic analysis identified a mutation in a gene called FANCM, which is involved in the cell's repair response to DNA damage and has recently been linked to breast cancer. This gene is mostly active in egg cells within the ovary. The sisters' protein made from this mutated copy of the gene was cut short compared with the protein produced by the mother's FANCM gene.
Due to the mutation, the sisters were more sensitive to chemicals that can damage the DNA, effectively making their genome less stable. The affected sisters also had higher levels of abnormalities in the chromosomes compared with their unaffected mother. Fouquet, Pawlikowska et al. then inserted a healthy version of the FANCM gene into the sisters' cells. This reversed the sensitivity of the sisters' cells to DNA-damaging chemicals.
The findings confirm a genetic link between primary ovarian insufficiency and genes responsible for DNA repair. Mutations in these genes can also make people more at risk of certain cancers. The findings point towards offering some women who have primary ovarian insufficiency in-depth genetic counselling with a long-term follow-up, when alterations of cancer-susceptibility genes are responsible for their condition. 47 years. Both patients had normal pilosity, breast and external genitalia, normal blood counts and liver balance, and had normal high-resolution karyotype and FMR1 gene. No abnormalities in skin pigmentation and skeletal development were observed.
Proband had menarche at 12 years of age, with irregular cycles (20-60 days). Hormonal contraception was started at the age of 16 years for menorrhagia and stopped four years later, after which menstrual cycles became highly irregular (21-140 days). At 24 years, she had hot flushes for about one year and spaniomenorrhea. Blood hormonal assays and ultrasonographic studies of the ovaries are reported in Table 1 . FSH level was high (41 IU/l) and AMH low. POI was diagnosed. At the age of 26, hormonal stimulation was attempted with no response. Soon after that, FSH increased to 120 IU/l and hormonal replacement was initiated.
Her sister had menarche at 12 years of age, with regular menses (23 days). Hot flushes started at the age of 20 years. At 22, she consulted for hot flushes and spaniomenorrhea. She had elevated (Integrative Genomics Viewer) shows a high coverage of the variant position and a large number of reads in the three individuals. (C) Sanger sequencing confirmed the presence of the variant at a homozygous state in both affected sisters and at a heterozygous state in both parents and their brother. (D) Structure of the FANCM gene and protein, and position of the causal variant. (E) Western blots of FANCM in the POI family. HEK293 cell transfected with a FANCM-specific siRNA were used to validate the specificity of the anti-FANCM antibody. To transiently deplete FANCM, HEK293 cells were transfected with 20 nmol/L of small interfering RNA (siRNA) targeting FANCM, 5'-GGC-UAC-GUC-CAG-GAG-CGC-3' with the CaCL 2 method. Panel present the result of a representative experiment on at least three independent analysis. DOI: https://doi.org/10.7554/eLife.30490.003 FSH (16 IU/l) and low E2 levels ( Table 1) . Incipient POI was diagnosed. As prolactin was elevated and brain MRI showed a suspected 3 mm adenoma, treatment with Parlodel was initiated. However, FSH remained elevated and AMH low ( Table 1) . At 23, hormonal stimulation was initiated with poor results. However, about 6 months later, she became spontaneously pregnant and gave birth to a healthy child.
Identification of a FANCM mutation by whole-exome sequencing and molecular studies
Both sisters with POI and their mother were studied by whole-exome sequencing, which generated~45 millions of mapped read pairs per sample (91% of targeted exome at !10X). Exome capture, sequencing and data processing were performed as described in (Fauchereau et al., 2016) . Variants were filtered according to the following criteria: minimum depth of 5 reads and variant quality of 20, with potential impact on transcript or protein, homozygosity in both affected sisters and heterozygosity in the mother and minor allele frequency (MAF) under 1%. The only variant fulfilling these criteria was the non-sense mutation chr14:45658326 C/T (rs147021911) in exon 20 of FANCM ( Figure 1B , Tables 2-3 ). According to the ExAC database, its MAF is 0.0013, slightly higher in the Finnish population (0.0089), with only one homozygous individual described in the ExAC database. The variant and its segregation in the family were verified by Sanger sequencing of the exon 20 of the FANCM ( Figure 1C ). This variant leads to the p.Gln1701* truncation at the protein level, which removes the C-terminal endonuclease and the FA associated protein 24 (FAAP24)-interaction domain ( Figure 1D ). FAAP24 mediates chromatin association of FANCM. EBV-immortalized cells were obtained from patient 2 and the mother. Immunoblot with an anti-FANCM antibody confirmed the expression of a truncated FANCM protein of~195 kDa in the cell line derived from the patient, whereas both the wild-type/WT (MW~235 kDa) and the truncated proteins were present in the heterozygous mother ( Figure 1E ). The expression level of the truncated protein was significantly reduced compared to the WT, suggesting that the mutation destabilizes either the protein or the corresponding mRNA (i.e., non-sense mediated decay).
No variants were observed in other FANC genes. Indeed, we have exhaustively looked for the presence of variants in a list of FA genes ( Table 4 ). The very good coverage of each gene (80-90X in the POI patients) excludes the possibility of having missed a variant due to a lack of coverage. The presence of heterozygous variants, both in coding regions and elsewhere (UTRs, the covered intronic sequences, etc.), in one or both POI patients, excludes the possibility of hemizygosity due to heterozygous deletions. The ratios of the number of reads of the alleles for these heterozygous variants were unbiased (i.e., close to 1) and argue against gene deletions. The detection of variants outside the coding portions of the exons also argues against the possibility of partial deletions. Exomebased CNV analysis showed that the detected CNVs were unrelated to the disease as they were either not common to the two sisters or were present in the mother. Finally, the total lack of correctly segregating variants (i.e common to both POI patients and heterozygous in the mother) in FA genes excludes the possibility of their involvement in the pathology.
FANCM is expressed in germ cells of human fetal and adult ovaries
FANCM expression was studied in germ cells of human fetal and adult ovaries. Human fetal material was obtained from the Antoine Bé clè re Hospital (Clamart, France) following legally-induced abortions or therapeutic termination of pregnancy. The identification of meiotic stages was performed in histological pieces that we have previously characterized (Frydman et al., 2017) and based on the chromatin features. qRT-PCR in human fetal ovaries demonstrated that FANCM mRNAs were expressed throughout ovarian development (5-32 weeks post-fertilization, wpf) ( Figure 2A ). Of note, expression tended to be higher than average in 14 and 17 wpf ovaries that are stages containing the highest proportion of germ cells progressing into meiotic prophase I.
Cell-sorting experiments conducted in 8-12 wpf ovaries indicated that FANCM transcripts were predominant in oogonial cells (D2-40-positive) compared to somatic cells ( Figure 2B) . Immunohistochemical studies in human fetal ovaries show that FANCM protein was present in the nuclei of oogonia but staining was stronger in pachytene stage oocytes (i.e., at 8 and 14 wpf respectively in (2) Total number of upstream, downstream, 5' and 3' UTRs, intronic, synonymous, splice site, missense, frameshift and stop variants in each gene.
(3) The presence of heterozygous variants in at least one of the patients excludes the possibility of hemizygosity for all genes (with the exception of the variant in FANCM that is homozygous) (4) The ratio between the number of reads for each allele was averaged for all heterozygous variants in the two affected sisters. A ratio close to one for each gene indicates no bias and argues against a possible deletion for the gene. Figure 2C ). Of note, staining localized along the chromosomes in pachytene cells that undergo meiotic recombination. FANCM was also observed in oocytes arrested at the diplotene stage of prophase I during the last trimester of pregnancy and in adults ( Figure 2C) . The co-staining with Synaptonemal complex protein 3 (SYCP3) or DEAD box protein 4 (DDX4/VASA) confirmed respectively the meiotic and germinal nature of the FANCM-positive cells ( Figure 2D) .
The FANCM mutation leads to hypersensitivity to Mitomycin C and altered FANCD2 monoubiquitination in response to DNA interstrand crosslinks but not to replication inhibition
Next, we monitored chromosome breakage in primary lymphocytes from the two patients and their mother. Baseline and DNA-damage induced chromosome breakage and rearrangement were blindly scored on 50 metaphases without treatment or after exposure to Mitomycin C (MMC) for 72 hr. In line with a role of FANCM in the maintenance of genome stability, the occurrence of chromosome breakages and rearrangements was higher in both POI patients than in their mother ( Figure 3A and  B) .
We also determined the impact of the FANCM truncating mutation on the sensitivity to Mitomycin C and on FANCD2 monoubiquitination in response to DNA interstrand crosslinks and replication inhibition. In response to MMC, primary lymphocytes from both patients had a reduced capability to monoubiquitinate FANCD2 ( Figure 3C) . The reduced level of FANCD2 in lymphocytes from POI patients is likely due to a reduced proliferation of their cells in culture conditions. Next, we determined the growth inhibition response of the lymphoblasts from POI patient-2 and her mother in response to MMC ( Figure 3D) , as previously described . The cells from the mother behaved like FANC-pathway proficient cells, while the response of the mutated cells was similar to that of FANCA-and FANCC-deficient lymphoblasts.
Finally, we assessed FANCD2 monoubiquitination in lymphoblastoid cells in response to MMC, that arrests replication by inducing DNA lesions ( Figure 4A ), or to two replication inhibitors, hydroxyurea (HU) and aphidicolin (APH), that block replication forks by poisoning DNA polymerases ( Figure 4B) . Surprisingly, whereas in response to MMC, FANCD2 monoubiquitination was clearly impaired in FANCMmut cells, those cells maintained a residual but detectable capability to monoubiquitinate FANCD2 after HU or APH treatments. Finally, consistent with a proficient DNA damage and stalled replication forks signaling in FANCM mutated cells, we failed to observe any major impairment in the MMC-phosphorylation of H2AX and CHK1 ( Figure 4A ) (Durocher and Jackson, 2001) .
To further validate that the identified bi-allelic mutation in FANCM was responsible for the MMC hypersensitivity observed in the patient's lymphoblasts, we transduced them with a FANCM-WT cDNA-expressing lentiviral vector (see Materials and methods). Transiently genetically complemented cells recovered a significant resistance to MMC ( Figure 3D) as well as an improved monoubiquitination of FANCD2 in response to MMC ( Figure 3E ).
Discussion
The two patients with POI studied here belong to a consanguineous family and are thus homozygous for the FANCM mutation inherited from their parents. Our FANCM mRNA and protein expression studies in the developing human ovary suggest that the expression of FANCM starts in mitotic germ cells (first trimester of pregnancy) notably along chromosome axes and increases at the onset of meiosis (second trimester) that are maintained up to the diplotene stage in follicles. Given the known role of FANCM to sustain primordial germ cell proliferation in mouse (Luo et al., 2014 ) and its conserved function during meiotic recombination (Lorenz et al., 2012; Crismani et al., 2012) , it is likely that both processes are sensitive to a FANCM mutation.
FANCM is a nuclear partner of the FANCcore complex, belonging to the FANC pathway that promotes DNA repair and safeguards replication. Indeed, FANCM is targeted to damaged DNA and/or (6) Among the 110 variants detected in the genes included in the FANC pathway, only the non-sense variant found in FANCM is homozygous in both patients, is rare (below 1% in ExAC database) and predicted as pathogenic. Figure 2 continued on next page stalled replication forks by its partners FAAP24, FANCM-interacting histone fold protein 1 (MHF1) and 2 (MHF2), where it recruits the FANCcore complex to monoubiquitinate FANCD2 and FANCI and coordinates DNA repair/replication rescue (Ceccaldi et al., 2016; Michl et al., 2016) allowing the faithful transmission of undamaged chromosome to the daughter cells. Consistently, the occurrence of chromosome breakages and rearrangements was higher in both POI patients than in their mother ( Figure 3A and B) . Our biochemical studies show that lymphocytes from both patients have a reduced capability to monoubiquitinate FANCD2 in response to MMC pointing to a defect in the activation of the FANCcore complex in FANCMmut cells. However the cells maintained a detectable capability to monoubiquitinate FANCD2 in response to HU or APH treatments.
A previous study links POI to other breast cancer genes such as BRCA1 (Oktay et al., 2010) . Although recent works established a link between the heterozygous c.5101C>T FANCM truncating mutation and BOC predisposition in the Finnish population (Kiiski et al., 2016 (Kiiski et al., , 2014 Neidhardt et al., 2017) , there is no history of BOC in the family investigated here. Interestingly, a few apparently healthy (i.e., without cancer) individuals homozygous for the c.5101C>T FANCM mutation were identified in previous studies (Kiiski et al., 2016 (Kiiski et al., , 2014 Neidhardt et al., 2017) . Indeed, the authors stated, by direct observation or by looking at registered clinical data, that none of them presented FA stigmata (although no data on age, sex or clinical findings was made available). This is in line with the fact that previously identified bi-allelic inactivating FANCM mutations in a few FA patients co-occurred with mutations in other FANC genes, which were indeed responsible for FA (Chang et al., 2014; Singh et al., 2009 ). This has led to the recent exclusion of FANCM from the group of the bona fide FA genes (Bogliolo and Surrallés, 2015) . Very recently two studies report that the phenotypes associated to FANCM biallelic mutations thus far are cancer predisposition, in particular early-onset breast cancer in females, and chemosensitivity (Catucci et al., 2017; Bogliolo et al., 2017) . In one study (Catucci et al., 2017) , two female patients out of five had premature menopause and one patient had an early reduction of the ovarian reserve according to her AMH levels.
Our results suggest that the cells that harbor biallelic c.5101C>T FANCM mutations maintain a FANCM residual activity allowing them to cope with the stalling of the replication forks during their normal proliferation in vivo, probably protecting individuals from the hematopoietic and developmental abnormalities that constitute the bona fide features of FA. However, the repair defects associated to the c.5101C>T truncating mutation that we describe likely leads to meiotic defects and oocyte apoptosis. Oocytes deficient for DNA repair may accumulate double-strand DNA breaks over time, resulting in reduced oocyte viability (Oktay et al., 2015) . Along similar lines, in Fancm -/female mice, the ovarian cortex is depleted of primary follicles and the number of developing follicles is reduced compared to WT ovaries. However, due to a bias against Fancm -/females, their fertility was not thoroughly investigated . Antral follicles were present, albeit in reduced number, which is consistent with the observations in our patients. Some follicles might escape the DNA repair defects and achieve maturation, as epitomized by the presence of antral follicles and corpora lutea in Fancm-deficient mice and by the spontaneous resumption of ovarian function with pregnancy reported in one of our patients. In conclusion, in this report, we document the first case implicating FANCM mutations in non-syndromic POI. Our findings clearly support a genetic link between infertility and DNA-repair/cancer genes and show the necessity to perform an enhanced genetic counseling of POI patients with a long-term follow-up. 
Materials and methods

Ethics statement
The study was approved by all the institutions involved. All participants gave informed consent for the study and the study was approved by the agence de Biomedecine (reference number PFS12-002).
Study approval
Written informed consent was received from participants prior to inclusion in the study and the institutions involved. 
Cell lines and infection with a lentiviral vector
Blood samples were collected for hormonal and genetic studies and for the production of EBVimmortalized lymphoblastoid cell lines, which was performed at the Genopole, Evry, France, following a standard in-house protocol. EBV-immortalized cells were obtained for patient 2 and her mother. HEK293 (Research Resource Identifier/RRID:CVCL_0045) cells and FANC pathway-proficient (HSC-93 (RRID:CVCL_G049)), and -deficient (HSC-72 (RRID:CVCL_G047), HSC-536 (RRID:CVCL_ G045) and GM16756 (RRID:CVCL_G041)) cells have been previously described . HSC-72, HSC-536 and GM16756 bring bi-allelic inactivating mutations in FANCA, FANCC and FANCD2, respectively. Lymphoblastoid cells were cultured in RPMI 1640 medium, supplemented with 12% FCS and antibiotics. Wild-type FANCM cDNA-expressing lentiviral vectors were a gift of M. Bogliolo (Dpt of Genetics and Microbiology, Universitat Autonoma de Barcelona, Spain). Production and titration of lentiviral particles were performed as described (Hamelin et al., 2006) . The infection was performed on retronectin-coated plates (TaKaRa Bio, CA, USA) and efficiency was assayed by testing GFP expression using flow cytometry.
Whole-exome and Sanger sequencing
Library preparation, exome capture, sequencing and data processing were performed by IntegraGen SA (Evry, France) according to their in-house procedures. Data analysis was performed as described in (Fauchereau et al., 2016) . Briefly, genomic DNA libraries were prepared from 600 ng of genomic DNA from three individuals (the mother and the two affected sisters) with NEBNext Ultra kit (New England Biolabs). Target capture, enrichment and elution were performed according to Figure 3 continued monoubiquitination in the same lymphocytes than in A and B. Immunoblot analysis were performed using mouse monoclonal anti-FANCM antibody (CV5.1), mouse monoclonal anti-FANCD2, (Santa-Cruz Biotechnology, Dallas, Texas, USA), rabbit anti-FANCA (Abcam, Cambridge, UK), mouse antivinculin (Abcam). Panel present the result of a representative experiment on at least three independent analysis. (D) MMC-induced growth inhibition in lymphoblasts from POI patient-2 and her mother compared to the response of cells from a FANCA (HSC-72), a FANCC (HSC-536), a healthy donor (HSC-93, WT) as well as to the patient cells transduced with a WT FANCM-cDNA. The points on the lines represent the means of 3 to 7 independent experiments ± S.D. *p<0,05, **p<0.01, Unpaired Student's T test. (E) The recovery of the MMC-induced FANCD2-monoubiquitination following FANCM expression in cells from patient 2 is shown. (1) and (2) indicate two independent experiments. Cells were treated with MMC (500 ng/ml) and proteins extracted 24 hr later. DOI: https://doi.org/10.7554/eLife.30490.009
The following source data is available for figure 3:
Source data 1. File presents the original data of each growth inhibition experiment used to calculate mean and S.D. for Figure 3D . DOI: https://doi.org/10.7554/eLife.30490.010 Figure 4 . The FANCM 5101C>T mutation leads to altered FANCD2 monoubiquitination in response to DNA damage but not to replication inhibition. Western blot showing FANCD2 monoubiquitination, CHK1 and H2AX phosphorylation in response to MMC (A), or HU or APH (B) in cells from patients 2 and her mother. FANCA (HSC-72) and FANCD2 (GM16756) lymphoblasts were used for comparison. Each panel presents the result of a Figure 4 continued on next page manufacturer's instructions and protocols (SureSelect Human All Exon Kits Version CRE, Agilent) without modification. Libraries were sequenced on an Illumina HiSEQ 2500 as paired-end 75 bp reads. Image analysis and base calling was performed using Illumina Real Time Analysis (RTA 1.18.64) with default parameters. The various metrics of the NGS sequencing are detailed in the Table 2 . The sequencing data was analyzed with the Illumina pipeline (CASAVA 1.8.2) for read alignment and variant calling, and an IntegraGen in-house pipeline was used for variant annotation. Annotation of kown variants was performed according to the following databases: dbSNP144 (RRID:SCR_ 002338), 1000 Genomes Project (release_v3.20101123) (RRID:SCR_008801), Exome Variant Server (ESP6500SI-V2-SSA137) (RRID:SCR_012761), HapMap3 (RRID:SCR_002846), ExAC r3.0 (RRID:SCR_ 004068), COSMIC 71 (RRID:SCR_002260), ClinVar 201507 (RRID:SCR_006169) and an Integragen internal database (containing 201 control exomes for SNPs and 130 control exomes for Indels). The variants were filtered using IntegraGen ERISv3 platform. The number of called variants and the effect of the various variant filters on the number of remaining candidate variants are shown in Table 3 .
The sequence of the exon 20 of the FANCM gene was verified by PCR amplification and Sanger sequencing from the genomic DNA of the available individuals, using the primers FANCM-Forward (5'-AAAACTCGACGTGCAGTAATG-3') and FANCM-Reverse (5'-GAGGTTTGAAGTCTGAGACTT-3').
Collection and processing of human ovaries
Human fetal material was provided by the Department of Obstetrics and Gynecology at the Antoine Bé clè re Hospital (Clamart, France) following legally induced abortions (first trimester) or therapeutic termination of pregnancy (second and third trimesters). The fetal age was evaluated by measuring the length of limbs and feet as previously described (Evtouchenko et al., 1996) . Adult human ovaries were provided by the Laboratory of Pathology of Gustave Roussy Institute (Villejuif, France) following prophylactic removal due to breast cancer. Adult ovaries did not present any pathological aspect, showing corpora lutea at various stages of regression compatible with at least three successive ovulatory cycles. All women provided an informed consent and this study was approved by the Biomedicine Agency (reference number PFS12-002). Tissue was either snap-frozen for RNA analysis of formalin-fixed for immunohistochemistry studies.
Expression time-course of FANCM transcripts in fetal ovaries
Human fetal material was obtained from the Antoine Bé clè re Hospital (Clamart, France) following legally-induced abortions or therapeutic termination of pregnancy. The fetal age was evaluated as previously described (Evtouchenko et al., 1996) . All women provided an informed consent and this study was approved by the Biomedicine Agency (reference number PFS12-002). After collection, fetal ovaries were stored in RNA lysis buffer (RLT) (Qiagen Courtaboeuf, France) for gene expression profiling. For some experiments human gonads were dissociated and germ and somatic cells were sorted using M2A (D240/PODOPLANIN) as previously described (Muczynski et al., 2012) . The M2A antigen was first reported as being present in testicular germ cells and germ cell tumors (Marks et al., 1999) . It has recently been shown that the M2A antigen is also expressed in female germ cells in the human developing ovary (Frydman et al., 2017) . Sorting was performed using a BD-Influx biohazard system (BD Biosciences; San Jose, CA; USA) with the D2-40-positive cells being mostly germ cells. Total RNA from fetal ovaries and sorted cells was extracted using the RNeasy Mini Kit (Qiagen). The 7900HT Fast Real-Time PCR System (Applied Biosystems, Foster City, CA) and SYBR-green labelling were used for quantitative RT-PCR (RT-qPCR). The comparative DDcycle threshold method was used to determine the relative quantities of mRNA using ACTB (ß-actin) mRNA as reference gene for normalization. Each RNA sample was analyzed in duplicate. The sequences of oligonucleotides used for amplification are:
FANCM ForwardExp (5'-GAGGAGCTTGTCCCGCTG-3'), ReverseExp: (5'-TGACTAGTTCTCTTACAACCTGGCAATA-3'); Figure 4 continued representative experiment on at least three independent analysis. Proteins were extracted 24 hr after exposure to genotoxins. DOI: https://doi.org/10.7554/eLife.30490.011
ClinVar 201507, https://www.ncbi.nlm.nih.gov/clinvar/ (RRID:SCR_006169) Exac database: http://exac.broadinstitute.org/ (RRID:SCR_004068) OMIM: http://omim.org/ (RRID:SCR_006437)
